{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T13:12:34Z","timestamp":1788441154552,"version":"build-2803163510"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ejmech.2023.115749","type":"journal-article","created":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T00:46:30Z","timestamp":1692492390000},"page":"115749","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Lead generation from N-[benzyl(4-phenylbutyl)carbamoyl]amino acid as a novel LPA1 antagonist for the treatment of systemic sclerosis"],"prefix":"10.1016","volume":"260","author":[{"given":"Yuki","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumito","family":"Uneuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Naruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Okumura-Kitajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromitsu","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yonemoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoh","family":"Toki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Kamigaso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyunya","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiken","family":"Tokura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kakinuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2023.115749_bib1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/CLEP.S191418","article-title":"Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease","volume":"11","author":"Bergamasco","year":"2019","journal-title":"Clin. Epidemiol."},{"key":"10.1016\/j.ejmech.2023.115749_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.ejmech.2023.115749_bib3","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I","article-title":"A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma","volume":"44","author":"Pope","year":"2001","journal-title":"Arthr. Rheum."},{"key":"10.1016\/j.ejmech.2023.115749_bib4","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1\u2010year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2023.115749_bib5","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1002\/1529-0131(199809)41:9<1613::AID-ART11>3.0.CO;2-O","article-title":"Case\u2010control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis","volume":"41","author":"Steen","year":"1998","journal-title":"Arthr. Rheum."},{"key":"10.1016\/j.ejmech.2023.115749_bib6","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/rheumatology\/keu285","article-title":"Old medications and new targeted therapies in systemic sclerosis","volume":"54","author":"Nagaraja","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejmech.2023.115749_bib7","doi-asserted-by":"crossref","first-page":"48737","DOI":"10.1074\/jbc.M206812200","article-title":"Serum lysophosphatidic acid is produced through diverse phospholipase pathways","volume":"277","author":"Aoki","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115749_bib8","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.7150\/jca.41841","article-title":"Lysophosphatidic acid receptors: biochemical and clinical implications in different diseases","volume":"11","author":"Xiang","year":"2020","journal-title":"J. Cancer"},{"key":"10.1016\/j.ejmech.2023.115749_bib9","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1111\/bph.12678","article-title":"Lysophospholipid receptor nomenclature review: IUPHAR Review 8","volume":"171","author":"Kihara","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115749_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nm1685","article-title":"The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak","volume":"14","author":"Tager","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2023.115749_bib11","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/art.30262","article-title":"Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma","volume":"63","author":"Castelino","year":"2011","journal-title":"Arthr. Rheum."},{"key":"10.1016\/j.ejmech.2023.115749_bib12","doi-asserted-by":"crossref","first-page":"168","DOI":"10.7150\/ijms.6.168","article-title":"Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis","volume":"6","author":"Tokumura","year":"2009","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.ejmech.2023.115749_bib13","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1124\/mol.64.4.994","article-title":"Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors","volume":"64","author":"Ohta","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2023.115749_bib14","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1124\/jpet.110.175901","article-title":"Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist","volume":"336","author":"Swaney","year":"2011","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115749_bib15","doi-asserted-by":"crossref","first-page":"7920","DOI":"10.1021\/jm301022v","article-title":"Discovery of highly selective and orally active lysophosphatidic acid receptor-1 antagonists with potent activity on human lung fibroblasts","volume":"55","author":"Qian","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2023.115749_bib16","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1021\/acsmedchemlett.6b00225","article-title":"Discovery of ONO-7300243 from a novel class of lysophosphatidic acid receptor 1 antagonists: from hit to lead","volume":"7","author":"Terakado","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115749_bib17","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1021\/acsmedchemlett.7b00383","article-title":"Discovery of a slow tight binding LPA1 antagonist (ONO-0300302) for the treatment of benign prostatic hyperplasia","volume":"8","author":"Terakado","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115749_bib18","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.cell.2015.06.002","article-title":"Crystal structure of antagonist bound human lysophosphatidic acid receptor 1","volume":"161","author":"Chrencik","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2023.115749_bib19","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.chest.2018.08.1058","article-title":"Randomized, double-blind, placebo-controlled, phase 2 trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of idiopathic pulmonary fibrosis","volume":"154","author":"Palmer","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.ejmech.2023.115749_bib20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00403-005-0635-z","article-title":"The bleomycin-induced scleroderma model: what have we learned for scleroderma pathogenesis?","volume":"297","author":"Yamamoto","year":"2006","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.ejmech.2023.115749_bib21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/exd.12752","article-title":"Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin","volume":"24","author":"Ohashi","year":"2015","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.ejmech.2023.115749_bib22","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s004030000180","article-title":"Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin mRNAs in human skin fibroblasts","volume":"292","author":"Yamamoto","year":"2000","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.ejmech.2023.115749_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1346-8138.2009.00764.x","article-title":"Animal model of systemic sclerosis","volume":"37","author":"Yamamoto","year":"2010","journal-title":"J. Dermatol."},{"key":"10.1016\/j.ejmech.2023.115749_bib24","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1021\/jo982059i","article-title":"Synthesis of enantiomerically pure N-tert-butanesulfinyl imines (tert-butanesulfinimines) by the direct condensation of tert-butanesulfinamide with aldehydes and ketones","volume":"64","author":"Liu","year":"1999","journal-title":"J. Org. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342300716X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342300716X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:56:55Z","timestamp":1759330615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342300716X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":24,"alternative-id":["S022352342300716X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115749","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lead generation from N-[benzyl(4-phenylbutyl)carbamoyl]amino acid as a novel LPA1 antagonist for the treatment of systemic sclerosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115749","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115749"}}